The Securities and Exchange Board of India (Sebi) issued an administrative warning to Dabur India on Friday for delaying the disclosure of a warning letter issued by the US Food and Drug Administration (USFDA) on July 24, 2026. According to reports from Business Standard, the company disclosed this development through a stock exchange filing on Friday. The violation concerned Regulation 30(6)(iii) of SEBI (LODR) Regulations, 2015, specifically read with sub-para 20 of Para A of Part A of Schedule III. The market regulator's letter was uploaded on the exchanges by Dabur India as part of its regulatory compliance. The warning letter from SEBI, specifically referencing Regulation 30 and sub-para 20 of Para A Part A Schedule III of the SEBI (LODR) Regulations, alleges that Dabur India failed to promptly disclose the USFDA warning letter.
In its official communication, Sebi stated that the non-compliance was viewed seriously by the regulator. As reported by Business Standard, the letter advised the company's board to exercise caution in the future to avoid similar lapses. The warning letter specifically noted that any repetition of such violation in the future would be viewed seriously and appropriate enforcement action would be initiated in accordance with the provisions of the SEBI Act, 1992, the Rules, the Regulations or Circulars issued thereunder. SEBI's Corporation Finance Department issued the warning letter on November 6, 2026, emphasizing the importance of timely information dissemination to stock exchanges. This administrative action is intended to caution the company against future lapses in disclosure timelines.
According to the regulatory letter uploaded by Dabur India, the communication from Sebi should be placed before the board of directors at the upcoming board meeting and its comments should be forwarded to the regulator. The company is also required to disclose this administrative warning letter to the stock exchanges under Regulation 30. This requirement ensures proper corporate governance processes are followed in addressing regulatory concerns. Dabur India has provided the requisite information as per Regulation 30 of the SEBI Listing Regulations, along with the SEBI warning letter, as annexures to its communication to the stock exchanges. The company has confirmed that the warning letter issued by Sebi had no impact on the company's financial operations and other activities.
In its filing to BSE and NSE, Dabur India stated that it has always been compliant with all SEBI Listing Regulations and will take necessary steps to address the concerns mentioned in the SEBI letter. The company affirmed that it will implement enhanced internal control mechanisms to ensure future compliance with SEBI's real-time disclosure requirements. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, ensuring transparency for investors. The intimation is also available on the company's website. The company has asserted its consistent compliance with SEBI Listing Regulations and stated that it will take necessary steps to address the concerns raised in the SEBI letter.
